Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT and Gemcitabine With Nab-paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma
NCT06393400Phase 1Active, not recruiting
- Start
- Jan 2025
- Primary completion
- Feb 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fecal Microbiota Transplantation Capsule in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Adverse Events at 4 years. Started Jan 2025; status: active, not recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06393400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393400.